Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,673 | 2,212 | 3,053 | 3,502 | 4,154 |
| Receivables | 4 | 1,205 | 22 | 124 | 1,783 |
| TOTAL | $2,928 | $5,282 | $4,401 | $5,345 | $9,091 |
| Non-Current Assets | |||||
| PPE Net | 124 | N/A | N/A | N/A | N/A |
| Other Non-Current Assets | 128 | 293 | 211 | 253 | 294 |
| TOTAL | $251 | $293 | $211 | $253 | $294 |
| Total Assets | $3,180 | $5,575 | $4,612 | $5,597 | $9,385 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 464 | 1,043 | 615 | 1,357 | 1,968 |
| Accrued Expenses | 1,454 | 1,046 | 889 | 549 | 447 |
| TOTAL | $2,305 | $2,513 | $1,761 | $2,207 | $2,802 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 1 | 130 | 10 | 3 |
| TOTAL | $0 | $1 | $130 | $10 | $3 |
| Total Liabilities | $2,305 | $2,514 | $1,891 | $2,217 | $2,805 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 3,541 | 2,968 | 2,371 | 1,405 | 1,306 |
| Common Shares | 0 | 0 | 0 | 0 | 1 |
| Retained earnings | -136,952 | -133,223 | -131,490 | -129,544 | -125,980 |
| Other shareholders' equity | -329 | -329 | -329 | -329 | -329 |
| TOTAL | $875 | $3,060 | $2,721 | $3,380 | $6,580 |
| Total Liabilities And Equity | $3,180 | $5,574 | $4,612 | $5,597 | $9,385 |